Isatuximab in multiple myeloma

Expert Opin Biol Ther. 2023 Apr;23(4):315-318. doi: 10.1080/14712598.2023.2193289. Epub 2023 Mar 24.

Affiliations

¹ Department of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
² Department of Experimental and Clinical Medicine, University "Magna Graecia" of Catanzaro, Italy.
³ Scientific Directorate IRCCS of Reggio Emilia, EmiliaRomagna, Reggio Emilia, Italy.
⁴ Biotechnology Research Unit, AO of Cosenza, Cosenza, Italy.
⁵ Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.

PMID: 36943846
DOI: 10.1080/14712598.2023.2193289

No abstract available

Keywords: Isatuximab; multiple myeloma; therapy.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Dexamethasone / therapeutic use
Humans
Multiple Myeloma* / drug therapy

Substances

isatuximab
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal
Dexamethasone